Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition

Author:

El Zaoui Ikram1,Bucher Maya2,Rimoldi Donata3,Nicolas Michael4,Kaya Gurkan5,Pescini Gobert Rosanna6,Bedoni Nicola1,Schalenbourg Ann4,Sakina Ezziat4,Zografos Leonidas4,Leyvraz Serge7,Riggi Nicolo6,Rivolta Carlo18,Moulin Alexandre P.4

Affiliation:

1. Department of Computational Biology, Unit of Medical Genetics, Lausanne University, Lausanne, Switzerland

2. Dermatology Unit, CHUV, Lausanne University, Lausanne, Switzerland

3. Ludwig Institute for Cancer Research, Epalinges, Switzerland

4. Jules-Gonin Eye Hospital, Lausanne University, FAA, Lausanne, Switzerland

5. Dermatology and Venerology Division, Dermatopathology Laboratory, Geneva University Hospital, Geneva, Switzerland

6. Experimental Pathology, Lausanne University Pathology Institute, Lausanne, Switzerland

7. Charité Cancer Comprehensive Center, Charité - Universitätsmedizin Berlin, Berlin, Germany

8. Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom

Publisher

Association for Research in Vision and Ophthalmology (ARVO)

Subject

General Medicine

Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3